Brief: Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis Merger
04/03/2025 14:07
March 4 (Reuters) - Alumis Inc ALMS.O: ACELYRIN DETERMINES UNSOLICITED INDICATION OF INTEREST FROM CONCENTRA BIOSCIENCES NOT REASONABLY EXPECTED TO RESULT IN A SUPERIOR PROPOSAL TO PLANNED ALUMIS MERGER Source text: ID:nGNX6jsj4z Further company coverage: ALMS.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial